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Abstract
Background—Methylome-wide association studies present a new way to advance the search for 
biological correlates for alcohol use. A challenge with methylation studies of alcohol involves the 
causal direction of significant methylation-alcohol associations. One way to address this issue is to 
combine methylome-wide association study (MWAS) data with genome-wide association study 
(GWAS) data.
Methods—Here, we combined MWAS and GWAS results for alcohol use from 619 individuals. 
Our MWAS data was generated by next generation sequencing of the methylated genomic DNA 
fraction, producing over 60 million reads per subject to interrogate methylation levels at ~27 
million autosomal CpG sites in the human genome. Our GWAS included 5,571,786 SNPs imputed 
with 1000 Genomes.
Results—When combining the MWAS and GWAS data, our top finding was a region in an 
intron of CNTN4 (p = 2.55x10−8), located between chr3:2,555,403–2,555,524, encompassing 
SNPs rs1382874 and rs1382875. This finding was then replicated in an independent sample of 730 
individuals. We used bisulfite pyrosequencing to measure methylation and found significant 
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association with regular alcohol use in the same direction as the MWAS (p= 0.021). Rs1382874 
and rs1382875 were genotyped and found to be associated in the same direction as the GWAS (p 
= 0.008 and p = 0.009). After integrating the MWAS and GWAS findings from the replication 
sample, we replicated our combined analysis finding (p=0.0017) in CNTN4.
Conclusions—Through combining methylation and SNP data, we have identified CNTN4 as a 
risk factor for regular alcohol use.
Keywords
methylation; next-generation sequencing; GWAS; CNTN4
Introduction
Alcoholism is a disorder characterized by compulsive and uncontrolled consumption of 
alcohol despite its negative effects on the drinker’s health, relationships and social standing. 
Alcohol use has a clear genetic component (Goldman et al., 2005) and genome-wide 
association studies (GWAS) have identified a number of putative risk loci (ex: (Edenberg et 
al., 2010, Schumann et al., 2011)). Most of these genetic variants, however, have modest 
predictive power, with the exception of Gelernter and colleagues whose study found variants 
in ADH1B to have reasonable predictive power (Gelernter et al., 2014). Current research is 
turning to epigenetic studies to supplement the search for biological correlates of alcohol 
use.
One of the most commonly studied epigenetic modifications is DNA methylation. 
Methylation occurs when a methyl group is attached at the carbon 5 position of a cytosine, 
and is most often, although not exclusively, found in the sequence context CpG. DNA 
methylation studies are a promising complement to genetic studies focusing on sequence 
variation. First, because methylation at critical sites can affect gene expression (Jones, 
2012), epimutations are more proximal to the outcome of interest than sequence variants and 
can therefore have higher predictive power. Second, methylation studies can improve 
disease understanding as they can, in principle, explain a variety of clinical disease 
phenomena such as genotype-environment interactions. Third, methylation is potentially 
reversible. One way to modify methylation sites, either reversing or causing methylation, is 
through pharmacological interventions (Fuks et al., 2000), which makes methylation sites 
potential drug targets. Fourth, the translational potential is profound. As they involve the 
stable methyl-cytosine bond that can be measured cost-effectively in “naked” (histone-free) 
DNA, these marks are potentially excellent biomarkers for eventual use in clinical settings 
to improve prognosis, diagnosis, and treatment.
Previous studies have investigated methylation and alcohol abuse or dependence. Studies of 
global methylation have found that alcoholic patients have higher levels of methylation 
compared with healthy controls (Bonsch et al., 2004, Thapar et al., 2012). Other studies 
have found associations between alcohol dependence and CpG methylation in known 
candidate genes for alcohol addiction, for example: SLC6A3 (Hillemacher et al., 2009), and 
OPRM1 (Zhang et al., 2012). More recent studies have used arrays to show that methylation 
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of many CpGs across the methylome are associated with alcohol dependence (Philibert et 
al., 2012, Zhao et al., 2013, Zhou et al., 2011).
These previous studies, however, have several limitations. First, there are over 27 million 
autosomal CpG sites in the human reference genome. The largest commonly used array, the 
Infinium HumanMethylation450 Bead Chip by Illumina, only covers 450K CpGs, mostly in 
gene promoters, suggesting that these array studies only surveyed a small fraction of the 
potentially methylated portion of the genome. Furthermore, much of the methylation 
relevant for individual differences may occur outside gene promoters (Irizarry et al., 2009). 
Second, the sample sizes in the previous studies are small and therefore lack adequate 
statistical power. For example, the largest sample size reported in the extant literature was 
20 sibling pairs (n=40) (Zhao et al., 2013). Third, instead of using primary human tissue, 
one of these studies used cell lines (Zhou et al., 2011), and another used DNA from Epstein 
Barr virus (EBV) transformed lymphocytes (Philibert et al., 2012), both of which may show 
different methylation profiles than primary human tissue. That is, when culturing cells, the 
conditions cannot fully mimic the human body and therefore DNA from cell lines may not 
accurately reflect the methylation occurring in humans. This is particularly true for EBV 
transformed cells, where the transformation itself affects methylation (Aberg et al., 2012a). 
Fourth, none of these previous studies considers the causal direction of significant 
methylation-alcohol associations. Specifically, they do not consider whether methylation is 
the result of alcohol exposure or if it is methylation is contributing to disruptive alcohol 
behaviors such as alcohol dependence. It is important to disentangle the two because it has 
implications for how significant methylation-alcohol sites can be utilized. For example, 
alterations in methylation levels as a result of exposure could potentially be useful early 
biomarkers of disease and may predict the risk of negative health or behavioral 
consequences. However, these might be poor drug targets for treating alcohol dependence as 
changing the methylation at the site will not affect drinking behaviors.
Our study aims to address these limitations. First, we interrogate all ~27 million autosomal 
CpG sites in a sample size of over 600 individuals. This study constitutes the largest alcohol 
methylation study to date in terms of the number of CpGs investigated and sample size. To 
increase confidence in our findings, we used a different platform to generate the methylation 
data for the replication, specifically the highly quantitative targeted pyrosequencing of 
bisulfite converted DNA.
The most comprehensive method for ascertaining methylation is whole genome sequencing 
of bisulfite converted DNA. However, due to the high costs of sequencing entire genomes 
and the large number of samples required for adequate statistical power in methylome-wide 
association studies (MWAS), this approach is currently not economically feasible for 
MWAS. A cost-effective alternative aims to sequence only the methylated part of the 
genome. Here, DNA is fragmented, the methylated fragments are captured, and then 
sequenced. The methyl-CpG binding domain (MBD) protein used in this study to capture 
the methylated genomic fraction strictly binds to methylated cytosines in the sequence 
context CpG (i.e. it will only bind to CpGs and not just a methylated cytosine). This is not a 
limitation as, with few exceptions (Lister et al., 2013), in most mammalian somatic tissues, 
DNA methylation occurs >99.75% of the time at CpG dinucleotides (Bernstein et al., 2007). 
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MBD-seq, next-generation sequencing combined with the use of the MBD protein, has 
already been demonstrated to be sensitive and capable of identifying differentially 
methylated regions (DMRs) (Serre et al., 2010), detecting previously reported robust 
associations (McClay et al., 2013) and producing findings that replicate when using “gold 
standard” technologies (Aberg et al., 2014). MBD-seq is quantitative, some subjects will 
have zero reads covering a CpG and others may not, but does not yield absolute methylation 
levels. This is, however, not critical for MWAS because we focus on differences between 
cases and controls or correlations with outcome variables. Absolute methylation levels are 
subtracted out from these differences and will not affect correlations that remain unchanged 
by linear transformations. The resolution of MBD-seq is approximately equal to the 
fragment size which is high enough to pinpoint a limited number of CpGs where the 
association occurs. Because short range correlations in the methylation status of CpGs seem 
pervasive across the methylome (Aberg et al., 2012b), in many cases it may not even be 
possible to improve the resolution obtained with MBD-seq as neighboring CpGs may have 
similar methylation statuses. All these properties make MBD-seq an efficient screening tool 
for large-scale MWAS to indentify DMRs that can then be investigated with more targeted 
assays.
Our approach to gain traction on the causal direction of effect is to combine MWAS data 
with GWAS data from the same samples. Because alcohol cannot alter sequence variation, 
the direction of effect in GWAS is assumed to be from the single nucleotide polymorphism 
(SNP) to alcohol use. Thus, for loci showing overlapping results between the MWAS and 
GWAS results, it is less likely that alcohol exposure effects would be driving the results.
MATERIALS AND METHODS
Discovery and Replication Sample
Table 1 describes the discovery and replication samples. Subjects from both samples were 
selected at random from national population registers in Sweden (Bergen et al., 2012). The 
subjects are essentially a population sample except that no one has a diagnosis of 
schizophrenia, which because of the low prevalence rate of schizophrenia, should not 
substantially alter the results. Current or past substance use was not an inclusion\exclusion 
criterion for study participation. All procedures were approved by ethical committees in 
Sweden and in the USA, and all subjects provided written informed consent.
The discovery sample included 619 individuals who responded to the binary alcohol use 
question which asked whether participants had ever considered themselves to have 
consumed alcohol regularly during their lifetime. This question does not distinguish between 
regular use and alcohol dependency. Alcohol dependency information was not collected on 
these participants. In the discovery sample, 94% of subjects self-identified as ever using 
alcohol regularly. The replication sample of 730 independent subjects, of whom 93% self-
identified as ever using alcohol regularly, was used to replicate key findings. DNA was 
extracted from the buffy coat of whole blood donated at local medical facilities.
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Stage 1: Discovery
MWAS: MBD-seq—Our MWAS sequencing approach (Aberg et al., 2012b) and 
computational analysis methods (Chen et al., 2013, van den Oord et al., 2013) have been 
described previously. Briefly, genomic DNA was fragmented with ultrasonication (Covaris) 
to a median length of ~150 bp, we used MethylMiner (Invitrogen, Carlsbad, CA) which 
employs MBD protein-based enrichment of the methylated DNA fraction, followed by 
single-end sequencing (50 bp reads) on the SOLiD platform (Life Technologies). As binding 
is better in CpG dense regions (Harris et al., 2010), we use an existing protocol variant that 
elutes the captured methylated fraction with 0.5 M NaCl to increase the relative number of 
fragments from CpG poor regions (Aberg et al., 2012b), which otherwise would not be as 
well covered (Bock et al., 2010), and improve coverage of the methylome. Library 
construction and next-generation sequencing was performed following the standard protocol 
for bar-coded fragment libraries (Life Technologies). Prior to alignment, but after deleting 
poor quality reads (> 2 missing color calls), we obtained an average of 67.3 million 
(SD=26.9 million) reads per sample.
MBD-seq can be used to obtain a relative quantitative methylation measure by summing the 
number of fragments covering each CpG site. However, methylation of any CpG in the 
entire fragment, not just the sequenced 50bp, could lead to its capture by MBD protein. 
Therefore, we estimated the fragment size distribution for each sample from the sequencing 
data, based on the distribution of reads around isolated CpGs. This non-parametric method 
has been validated against paired-end libraries where fragment size is known (van den Oord 
et al., 2013). The sample-specific estimated fragment size distribution was then used to 
calculate the probability for each read that the fragment it is tagging covers the CpG under 
consideration. Coverage estimates for each of the autosomal CpGs in the reference genome 
were then calculated for each subject by taking the sum of the probabilities that all 
fragments in its neighborhood cover the CpG (van den Oord et al., 2013).
To reduce the size of the data set, the CpGs were adaptively combined by collapsing highly 
inter-correlated coverage estimates at adjacent CpG sites into a single mean coverage 
estimate (Aberg et al., 2012a). This resulted in 5,074,560 CpG “blocks”. Prior to association 
testing, we identified 800,140 blocks with very low (< 99% of noise) levels of coverage. 
Eliminating these likely non-methylated sites left 4,274,420 blocks for the MWAS.
MWAS association testing—To test for association, we regressed the coverage of the 
remaining “blocks” on regular alcohol use. In MWAS, there are multiple differences (e.g. 
diet and medication use) between individuals that are unrelated to alcohol use but may affect 
the methylome. A variety of efforts were made to control for such confounders which are 
described in the Supplemental Material.
To account for multiple testing, we controlled the false discovery rate (FDR) at the 0.1 level 
(van den Oord and Sullivan, 2003). This means that on average 10% of the methylation sites 
declared significant are expected to be false discoveries. Operationally, the FDR was 
controlled using q-values that are FDRs calculated using the p-values of the individual tests 
as thresholds for declaring significance (Storey and Tibshirani, 2003).
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GWAS—Details of the genotyping and quality control methods have been previously 
described (Bergen et al., 2012). Briefly, most subjects were genotyped with Affymetrix 6.0 
chips (Affymetrix, Santa Clara, CA, USA) with the remainder genotyped with the 
Affymetrix 5.0. SNPs with minor allele frequencies less than 1%, or departure from Hardy-
Weinberg equilibrium (p < 1x10−6) were excluded. Individuals with genotype call rates less 
than 95% and a randomly selected member of any pair of subjects with high relatedness (π̂> 
0.20) were excluded.
Imputation was conducted using MaCH (Li et al., 2010) for the genotype phasing and 
Minimac (Howie et al., 2012) for the imputation. Our genotypes were imputed against 
autosomal data from 1000 Genomes (Version 3) and we retained only SNP dosages imputed 
with high confidence (INFO > 0.50). After imputation and quality control, there were 
5,571,786 SNPs included in the analysis. Association testing was conducted by regressing 
regular alcohol use on the imputed SNP values with one multidimensional scaling (MDS) 
component, age and sex included as covariates to control for ancestry, age effects and 
gender differences. As in the MWAS, we controlled the FDR at the 0.1 level.
Combined Analysis—We used Fisher’s method (Fisher, 1948) to combine the MWAS 
and GWAS results. Because there are multiple mechanisms that may explain the 
associations for both CpGs and SNPs, we chose to use Fisher’s method because it does not 
require any specific mechanism and can therefore capture all mechanisms that may explain 
the associations. Fisher’s method assumes that the data being combined are tested under the 
same null hypothesis of no effect of the locus. Under the null hypothesis, the tests of the 
MWAS and GWAS data are independent unless their errors are correlated, which is unlikely 
because the data were produced using two different platforms. The independence of error 
terms would not hold if the alternative were true, which is not relevant for the current 
analyses. To show that when testing under the null the p-values are independent, we 
correlated the p-values from the MWAS and GWAS and obtained a Pearson correlation of 
0.0167 which suggests that the p-values are uncorrelated. Additionally, a plot of the MWAS 
vs. the GWAS p-values (Figure S3) showed no discernible relationship between the two. 
Both pieces of evidence demonstrate that under the null, the tests are independent.
Fisher’s method first takes the natural logarithm of each p-value, multiplies each result by 
-2, and then sums them. The resulting sum is distributed as a chi-square statistic with 2L 
degrees of freedom, where L is the number of p-values. Only SNPs that were located within 
the boundaries of a methylation block were used. In order to be included in the combined 
analysis, a site must have p-value < 0.01 on both the MWAS and GWAS to avoid an 
extreme p-value on only one platform dominating the overall results. We tested several other 
potential p-value thresholds for inclusion into the combined analysis, specifically 0.10, 0.05, 
0.01, and 0.001, and found the results to be robust against different thresholds.
Step 2: Replication
Pyrosequencing—For replication purposes we used pyrosequencing, which allows for 
targeted sequencing of bisulfite converted DNA with high quantitative accuracy (Reed et al., 
2010). Genomic DNA was bisulfite converted using Epitect 96 (Qiagen) and reactions were 
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carried out using the PyroMark system according to standard protocols (Qiagen). Table S4 
provides primer sequences. Controls including five DNA samples with known methylation 
levels (0%, 25%, 50% 75% and 100% methylation, created using methylated (#59665) and 
unmethylated (#59655) EpiTect Control DNA) were run for each assay and at least two 
controls of known methylation levels were included on each plate. We used logistic 
regression to test for association between regular alcohol use and methylation in the 
pyrosequencing data. Age, sex and plate indicator variables were included in the logistic 
regression to control for age and sex differences, and potential batch effects.
RESULTS
Discovery stage
MWAS with alcohol use—We used the quantitative coverage estimates for ~4.3 million 
CpG blocks as input for multiple regression analyses to test for association with regular 
alcohol use. A variety of efforts were made to control for potential confounders including 
controlling for age and sex, regressing out potential assay-related technical artifacts, and 
incorporating principal component analysis (PCA) to capture any remaining unmeasured 
potential confounders. The quantile-quantile (QQ) plot for this analysis (Figure 1A) 
indicates an enrichment of small p-values with little inflation (λ=1.04). Our test statistic 
inflation parameter λ of 1.04 was higher compared to what is commonly observed in 
GWAS. This lambda is unlikely an artifact. After performing a square root transformation to 
normalize the data and mitigate the effects of possible outliers, λ did not change. Instead, 
this λ reflects that methylation studies are more akin to gene expression studies that typically 
show many correlated effects with relatively large effect sizes.
Thirty-three DMRs passed our FDR threshold of q-value < 0.1 for genome-wide 
significance ensuring that only 10% of the findings are expected to be false discoveries. 
Table S2 provides details for all 33 DMRs below the FDR. The top finding (p = 1.93x10−9, 
q = 0.008) was a block with two CpGs located in an intergenic region of chromosome 20.
GWAS with alcohol use—We performed a GWAS for regular alcohol use with 
5,571,786 SNPs, imputed using 1000 Genomes, with one MDS component covariate to 
control for population stratification. A QQ plot (Figure 1B) and λ of 1.00 showed no 
inflation of the test statistics. There were 144 SNPs that reached our genome-wide 
significance threshold of q < 0.1, with a minimum p-value of 1.22x10−9 (a full list of results 
with q < 0.1 is given in the Supplementary Material). As 1000 Genomes imputation results 
in a dense SNP panel, many of the significant SNPs were in high linkage disequilibrium 
(LD) with each other meaning that the number of unique associated loci is less than the 
number of associated SNPs. For example, there were 20 SNPs in high LD (0.96 < r2 < 0.99) 
located in an intron of CNTN4 on chromosome 3 and 8 SNPs on chromosome 12 found in an 
intron of CHPT1.
Combined MWAS and GWAS Results—We combined our MWAS and GWAS results 
using Fisher’s method (Fisher, 1948). The QQ-plot for the combined analysis (Figure 1C) 
shows that there is an enrichment of small p-values and there is little evidence of inflation (λ 
=1.008). There were 17 signals with a q < 0.1 (Table 2; Figure S2). The top two results from 
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the combined analysis are two SNPs overlapping with a methylation block located in an 
intron of CNTN4. Only one of the top 17 findings was located in a CpG island or shore, 
2000 bp flanking region of a CpG island. Other top findings were located in introns or 
DNAse clusters (Table 2).
Replication of CNTN4
Given the converging evidence between the MWAS and GWAS results for CNTN4 on 
chromosome 3, we conducted further assays and analyses of this locus in an independent 
sample of 730 individuals (Table 1). First, we generated the methylation data using 
pyrosequencing of bisulfite converted DNA. The region implicated in CNTN4 on 
chromosome 3 by the combined analysis had two CpGs at coordinates 2,555,483 and 
2,555,524 that were highly correlated with each other. As it is practically impossible to 
design a high quality pyrosequencing assay that would target both these CpG sites, we 
instead used a high quality assay that targeted only the CpG at 2,555,524. Given that the two 
sites are highly correlated, the methylation measure from this assay should give a good 
estimate of the methylation levels at both sites. The regression results indicated that the CpG 
site was significantly associated with regular alcohol use (p = 0.021) and in the same 
direction as the discovery MWAS (βdiscovery =−2.71; βreplication = −0.06). These results 
remained significant (Table S5) even when regressing out other substance use covariates 
that are often comorbid with alcohol use (i.e. smoking and narcotic use).
We also replicated our GWAS findings. GWAS data from Affymetrix 6.0 chips were 
available for the replication sample and replication was carried out in the same manner as 
the discovery GWAS. Of the 144 significant SNPs in the discovery GWAS, only 16 were 
considered to be replicated (Table S3) as they had a p-value < 0.05 and the same direction of 
effect in both the discovery and replication samples. All 16 of these SNPs were located in 
CNTN4 and are in high LD with one another. Considering specifically rs1382874 and 
rs1382875, the two SNPs implicated in the combined analysis CNTN4 finding, both SNPs 
were associated with regular alcohol use (p = 0.008 and p = 0.009, respectively) in the 
replication even after controlling for multiple testing. Two additional SNPs on chromosome 
14 had p-values < 0.05, but the direction of effect was not the same in the replication as in 
the discovery GWAS, and therefore we considered these SNPs to not have replicated.
Following the same procedure as in the discovery sample, we then replicated our combined 
GWAS and MWAS finding, by using Fisher’s method to combine the results. The combined 
one-sided p-values were 0.0018 and 0.0017 for rs1382874 and rs1382875, respectively. In 
contrast to the GWAS which implicated 16 SNPs, the combined analysis only implicated 
two SNPS. This is likely due to correlations among methylation sites being much more 
localized when compared to LD between SNPs (Kumar et al., 2015).
Bioinformatic investigations of these two SNPs showed that they were located in an intron 
of CNTN4. These SNPs, rs1382874 and rs1382875, are 102 and 41 base pairs away, 
respectively, from the CpG site that was pyrosequenced. The functional relevance of these 
two SNPs was investigated using the SNP Function Prediction (FuncPred) (Xu and Taylor, 
2009) (http://snpinfo.niehs.nih.gov). The results indicated that both SNPs may have 
regulatory potential as predicted by the ESPERR (evolutionary and sequence pattern 
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extraction through reduced representations) method (Taylor et al., 2006). We also examined 
functional potential by seeing if the two CpGs in the region were encompassed by 
transcription factor (TF) binding sites. We used empirical data for TF binding from the 
ENCODE project, in addition to conserved TF recognition sequences across humans and 
rodents from the TRANSFAC database (Matys et al., 2006). We included a flanking region 
of ± 250 bp to account for the maximum length of sequenced fragments in our MBD-seq 
experiments around the two CpGs that bounded the region at chr3:2,555,403 and chr3: 
2,555,524. This region encompassed several TFBS according to TRANSFAC. These 
included myocyte-enhancer factor 2 (MEF2), TATA-binding protein (TBP), octamer 
transcription factor (OCT1) and signal transducer and activator of transcription 3 (STAT3). 
These sites were not detected with ENCODE empirical data.
We then investigated possible mechanisms through which CNTN4 may affect regular 
alcohol use. Given that both methylation and SNPs are involved, one possibility is that there 
is a CpG-SNP, which is a SNP that creates or destroys CpGs. Rs1382875 directly overlaps 
with a CpG and can therefore be considered a CpG-SNP. We tested whether rs1382875 was 
operating under a CpG-SNP mechanism by interrogating whether methylation was 
associated with the number of copies of the G allele, which creates a CpG site, an individual 
had. The regression indicated that the CpG-SNP is potentially regulating methylation in the 
region (p = 0.047).
DISCUSSION
By integrating MWAS and GWAS data were able to identify two SNPs in CNTN4 that 
influence regular alcohol use. Even without considering the methylation data, the GWAS 
results implicated 16 SNPs in CNTN4 spanning a 7Kb region. However, using both GWAS 
and methylation data adds additional confidence to the robustness of our findings as the two 
different technologies converging on the same solution reduces platform specific errors 
(Niculescu et al., 2000). Furthermore, it enabled us to fine-map the location of the putative 
casual sites from 16 SNPs implicated by the GWAS to two potential SNPs, because in 
contrast to LD between SNPs, correlations among methylation sites tend to be much more 
localized (Kumar et al., 2015).
CNTN4 (contactin 4) locus on chromosome 3p26.3 is a member of the contactin family of 
immunoglobulins that are expressed predominantly in the central nervous system (Shimoda 
and Watanabe, 2009). The genes in this family function as cell adhesion molecules, guiding 
axon growth during development, and have roles in modulating synaptic transmission and 
plasticity (Dityatev et al., 2008). Recently, two SNPs at CNTN4 were associated with 
measures of human brain network connectivity (Jahanshad et al., 2013) indicating that 
genetic variants at CNTN4 have the potential to affect brain function. Indeed, evidence has 
shown that CNTN4 is associated with developmental disorders including 3p deletion 
syndrome (Fernandez et al., 2004) and autism (Roohi et al., 2009). In summary, evidence 
indicates that CNTN4 is of critical importance for human brain development and function 
and, when disrupted, can lead to neurodevelopmental disorders.
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Some previous evidence also indicates a role for CNTN4 in alcohol use. An early GWAS 
reported an association of a pathway containing CNTN4 and level of response to alcohol, a 
measure inversely correlated with problem drinking behavior (Joslyn et al., 2010). A later 
GWAS found SNPs in close proximity to CNTN4 to be associated with co-morbid alcohol 
dependence in bipolar patients (Kerner et al., 2011). Studies have linked CNTN4 to olfaction 
and development of olfactory neurons (Mimmack et al., 1997). Therefore, taste preference 
for alcohol could be speculated as a mechanism by which CNTN4 could influence drinking. 
Although further research is needed to define specific mechanisms by which CNTN4 
influences regular alcohol use, it is a plausible candidate.
There are several scenarios that can explain the relationship between genetic variation, 
methylation and alcohol use we see in our study. One mechanism involves SNPs that create 
or destroy CpGs, called CpG-SNPs. The signal in CNTN4 was produced by CpG-SNP which 
suggests that allele frequency differences between cases and controls at the CpG-SNP may 
also influence methylation differences there. The statistical power is generally low to detect 
methylation differences caused by CpG-SNPs. In the case of rs1382875 in the replication 
study, with minor allele frequencies of 0.25 and 0.37 in cases and controls respectively and 
0.12% of the variance in methylation explained by the SNP, a sample of just over 1300 is 
required to achieve 80% power to detect methylation differences. Our sample size of 619 
makes it possible that we have detected methylation differences related to allele frequency 
differences between cases and controls. However, we cannot rule out an alternative 
mechanism in which methylation plays an active role in regular alcohol use. For example, 
similar to SNPs, methylation in critical sites can inhibit the binding of TFs to their 
recognition elements (Prendergast and Ziff, 1991), resulting in gene silencing.
Assuming that the methylation signal in the region is tagging a causal SNP, this motivates 
the investigation for potential functional SNPs in the region. We examined the functional 
relevance of SNPs within the suggested region and found that two SNPs, rs1382874 and 
rs1382875, may have regulatory potential, as predicted using the ESPERR (Taylor et al., 
2006). This method allows for classification of functional versus neutral genomic regions, 
based on cross-species sequence homology, GC content and other metrics. It has been 
shown to accurately classify a range of functional elements, including binding sites for cis-
acting factors, DNaseI hypersensitive sites and developmental enhancers.
As the signal may involve an active role of methylation, we also examined genomic features 
of the implicated region. We found that the methylation site encompassed several TF 
binding sites which is relevant because methylation in critical sites can inhibit the binding of 
TFs to their recognition elements (Prendergast and Ziff, 1991), resulting in gene silencing. 
Specifically, the methylation site overlapped with TF binding sites for MEF2, TBP, OCT1, 
and STAT3, according to TRANSFAC (Matys et al., 2006). MEF2 is a regulator of cellular 
differentiation and plays a critical role in embryonic development, in addition to 
involvement in neuronal differentiation and regulation of stress response in adults (Potthoff 
and Olson, 2007). TBP is a generic TF that is part of the basic transcriptional machinery, 
while OCT1 is also widely expressed but necessary for cellular stress response. STAT3 has 
a role in regulating synaptic plasticity in the central nervous system (Nicolas et al., 2013). 
Notably, reduced expression of STAT3 has been shown in peripheral blood of non-human 
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primates following chronic ethanol consumption (Asquith et al., 2014). The overlap of the 
region of interest with TF binding sites suggests a potential mechanism by which 
methylation may influence alcohol use.
While the methylation finding in blood is interesting because of the potential to indicate 
liability for alcohol use or other alcohol-related health outcomes such as inflammation, it is 
important to examine how methylation may play a role in other tissues which might be more 
relevant for addiction, such as brain. Whether blood is the most appropriate tissue for 
methylation addiction studies has been a discussion point (Wong et al., 2011) because 
methylation patterns can be tissue specific. If the methylation signal is merely tagging 
differences in allele frequencies the issue of using blood is less relevant in the context of our 
CNTN4 finding because methylation would play no causal role and merely tags a SNP effect 
that is not tissue specific. If, however, there is a causal role of the methylation at the CpG-
SNP site the issue is relevant. Several studies have found a high degree of overlap between 
methylation in blood and brain tissue (Aberg et al., 2013, Davies et al., 2012). These studies, 
however, considered all CpGs, not specifically CpG-SNPs. We therefore conducted a study 
to examine the overlap in methylation status of CpG-SNPs in blood and brain. The blood 
methylation data came from an MBD-seq study of 1459 blood samples (Aberg et al., 2014). 
The 75 brain samples from the prefrontal cortex, Broadmann Area 10, on which we 
performed MBD-seq, were obtained from the Stanley Medical Research Institute. Using the 
99th percentile of coverage at non-CpGs sites (i.e. MBD-seq captures only CpG 
methylation, as these sites are at least 400 bp away from the nearest CpG they cannot be 
methylated and any reads covering them represent “noise”) as a threshold below which we 
considered sites to be unmethylated, we found that 68.3% and 67.7% of CpG-SNPs where 
likely methylated in blood and brain, respectively. The overlap of methylated sites in blood 
and brain was high, as 94% of the methylated sites in blood were also methylated in brain. 
One caveat to these results is that methylation patterns in the prefrontal cortex may not be 
similar to patterns in other brain regions. Research has shown that there are some differences 
in individual sites between brain regions, but overall the correlation between methylation in 
different brain regions is as high as 0.76 (Davies et al., 2012). This evidence suggests that 
the methylation of CpG-SNPs in blood likely mirror the methylation of the same site in 
brain. Thus, it is not unreasonable to hypothesize about casual processes in brain based on 
our findings in blood.
In addition to the MWAS results that overlapped with the GWAS results, there were several 
MWAS results that did not overlap. We further investigated these top non-overlapping 
MWAS results using pathway analyses, but found that they did not organize into significant 
pathways. This is consistent with the idea of alcohol exposure causing methylation changes 
in blood that may not result in coordinated, functional biological processes. Even though 
these significant methylation-alcohol associations may reflect alcohol exposure, they have 
the potential to be useful as biomarkers of exposure to alcohol, and potential predictors of 
health and risk outcomes associated with detrimental alcohol use. Further investigation of 
these signals is therefore warranted.
Through combining methylation and GWAS data, we have identified CNTN4 as a risk factor 
for alcohol use. Strengths of the methylation aspect of this study included the utilization of a 
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much larger sample size compared to previous studies with arrays. Also, our use of next-
generation sequencing results in an improvement in the number of sites interrogated over 
arrays. In addition to replicating our separate MWAS and GWAS results, we were able to 
replicate our combined CNTN4 finding in an independent sample using a different 
technology to measure methylation, providing further evidence that this is a true finding. 
There may be two possible mechanisms which explain the CNTN4 finding: the methylation 
differences are tagging allele frequency differences at a CpG-SNP or there is an active role 
for methylation influencing alcohol use.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
QQ plots for A) MWAS, B) GWAS, and C) Combined MWAS and GWAS results
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